A61K 31/4436
Containing a heterocyclic ring having sulfur as a ring hetero atom
Official title: containing a heterocyclic ring having sulfur as a ring hetero atom
A61K31/4436 (Containing a heterocyclic ring having sulfur as a ring hetero atom) appears on 468 US grants and 789 published applications in this corpus.
Search patents in A61K- Granted patents
- 468
- Published applications
- 789
- Assignees
- 407
- Inventors
- 2,129
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 6 | 0 |
| 2001 | 7 | 4 |
| 2002 | 3 | 9 |
| 2003 | 6 | 17 |
| 2004 | 6 | 15 |
| 2005 | 9 | 15 |
| 2006 | 8 | 17 |
| 2007 | 2 | 11 |
| 2008 | 3 | 8 |
| 2009 | 5 | 15 |
| 2010 | 8 | 24 |
| 2011 | 5 | 25 |
| 2012 | 9 | 30 |
| 2013 | 21 | 37 |
| 2014 | 33 | 45 |
| 2015 | 26 | 57 |
| 2016 | 38 | 40 |
| 2017 | 46 | 52 |
| 2018 | 29 | 55 |
| 2019 | 54 | 44 |
| 2020 | 29 | 37 |
| 2021 | 23 | 52 |
| 2022 | 23 | 39 |
| 2023 | 24 | 27 |
| 2024 | 15 | 39 |
| 2025 | 14 | 40 |
| 2026 | 7 | 35 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for preventing skin toxicities caused by biological targeted cancer drugs29 Sep 2026US 12,746,219 B2Hadasit Medical Research Services and Development Ltd.
- Compositions comprising HDAC inhibitors and retinoids22 Sep 2026US 12,740,953 B2The Regents of the University of California
- Tetrahydrothieno pyridine derivatives as DDRs inhibitors1 Sep 2026US 12,723,052 B2Chiesi Farmaceutici S.P. A.
- Bacterial DNA gyrase inhibitors and methods of use thereof25 Aug 2026US 12,714,692 B2The Florida International University Board of Trustees
- Compositions and methods for providing cardioprotective effects9 Jun 2026US 12,648,938 B2Cornell University
- Methods of treating diseases and disorders associated with foxp3 expression8 Oct 2026US 2026/0306482 A1Northwestern University
- Targeting rnas associated with tauopathies with small molecules8 Oct 2026US 2026/0308158 A1University of Florida Research Foundation, Inc.
- Neuroactive androgen receptor modulators and use thereof1 Oct 2026US 2026/0294908 A1ENDOCHEM PHARMACEUTICALS (BEIJING) CO., LTD. Beijing
- Cyclic vinyl sulfone wrn inhibitors1 Oct 2026US 2026/0297070 A1Nimbus Wadjet, Inc.
- Hdac1/2 selective inhibitor and use thereof1 Oct 2026US 2026/0297110 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Most cited
By later US patents
- Small organic molecule regulators of cell proliferation110US 7,115,653 B2Curis, Inc. · 2006
- Adenosine receptor ligands and their use in the treatment of disease82US 6,586,441 B2Hoffman-La Roche Inc. · 2003
- Aryl- or heteroaryl-substituted benzene compounds82US 8,410,088 B2Eisai R&D Management Co., Ltd. · 2013
- Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, Alzheimer'S disease, sleep disorders, Parkinson'S disease, AIDS, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like81US 8,741,336 B2Chrono Therapeutics, Inc. · 2014
- Small organic molecule regulators of cell proliferation75US 6,683,192 B2Curis, Inc. · 2004